Durable humoral responses after the second anti‐SARS‐CoV‐2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors

Abstract

S.C., E.L.P., F.M., K.K., R.P., A.J.I.: none; R.S.T. and M.O.M. are listed as listed as inventors for the Hybrid DABA assay (patent file number: IRN.FID4816059) and acknowledge the support of UK Research and Innovation (UKRI). J.F.A. and D.M. are grateful for the support of the Imperial College National Institute of Health Research (NIHR) Biomedical Research Centre and Blood Cancer UK Vaccine Research Collaborative, a partnership between Blood Cancer UK, Myeloma UK, Anthony Nolan and the British Society of Haematology (Grant 21011). D.M.: research funding from Incyte. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.